Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Azacitidine 26venetoclax 20Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 13Biopsy 13fludarabine 12Specimen Handling 12Tacrolimus 11Mycophenolic Acid 11Decitabine 10Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 9Injections 8Cytarabine 8Busulfan 8decitabine and cedazuridine drug combination 7Melphalan 7X-Rays 5Hematopoietic Stem Cell Transplantation 5Cyclosporine 5Sirolimus 4ruxolitinib 3olutasidenib 3enasidenib 3cedazuridine 3Magnetic Resonance Spectroscopy 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × seclidemstat × 1 year × Clear all
NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡